Recombinant Human Erythropoietin Therapy in Anemia Accompanied by Chronic Renal Failure. |
Dong Kyu Jin, Hae Il Cheong, Yong Choi, Kwang Wook Ko |
Department of Pediatrics, Seoul National University, College of Medicine, Seoul, Korea |
만성신부전에 병발한 빈혈에서 재조합형 인형 에리트로포에틴
(recombinant human erythropoietin) 의 치료 효과* |
진동규, 정해일, 최용, 고광욱 |
서울대학교 의과대학 소아과학교실 |
Received: 29 January 1990 • Accepted: 23 March 1990 |
|
Abstract |
A clinical study was carried out to evaluate the efficacies of rHuEPO (recombinant human
erythropoietin) in anemia of 7 chronic renal failure patients under dialysis at Seoul National
University Children's Hospital from Feb. 1989 to Nov. 1989.
The results were as follows;
- 1) There was progressive increase of hematocrit levels in all 6 hemodialysis patients and mainte-
nance dosage of rHuEPO to sustain hemoglobin 10~12 gm/dl was 100—125 U/kg/week and the
patients did not need the transfusion any more.
2) With the use of 250 U/kg/week of rHuEPO, there was no need of transfusion and hematocrit
increased to 30% in a continuous ambulatory peritoneal dialysis patient.
3) There was progressive decrease of serum ferritin level over 8 months.
4) The complications of rHuEPO were transient hypertension and increase of BUN and creatinine
in 1 case, and frequent clotting of dialyzer in 2 cases.
5) The beneficial effects of rHuEPO included increase of appetite, the activity of living and smooth
sleep at night.
6) Therefore, rHuEPO can be used safely to improve the anemia accompanied by chronic renal
failure and obviates the need of transfusion. |
Key Words:
rHuEPO, Chronic renal failure, Anemia |
|